Anacetrapib and Dalcetrapib: Two Novel Cholesteryl Ester Transfer Protein Inhibitors

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial

(2010) Evan A. Stein et al.   EUROPEAN HEART JOURNAL

Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing

(2010) Michael Derks et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Effect of Hepatic Impairment on the Pharmacokinetics of Dalcetrapib

(2010) Mary Phelan et al.   Journal of Clinical Lipidology

Coadministration of Dalcetrapib With Pravastatin, Rosuvastatin, or Simvastatin: No Clinically Relevant Drug-Drug Interactions

(2010) Michael Derks et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Biochemical characterization of cholesteryl ester transfer protein inhibitors

(2010) Mollie Ranalletta et al.   JOURNAL OF LIPID RESEARCH

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

(2010) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome

(2009) Gregory G. Schwartz et al.   AMERICAN HEART JOURNAL

The Pharmacology and Off-Target Effects of Some Cholesterol Ester Transfer Protein Inhibitors

(2009) Menno Vergeer et al.   AMERICAN JOURNAL OF CARDIOLOGY

Safety and Tolerability of Dalcetrapib††Conflicts of interest: Dr. Stein has received grants for studies of lipid-modifying agents, has received consulting fees and honoraria for professional input regarding agents to modify lipid profile, and/or has delivered lectures for the American Association for Clinical Chemistry, Washington, District of Columbia; Abbott Laboratories, Abbott Park, Illinois; AstraZeneca, Wilmington, Delaware; the United States Food and Drug Administration, Washington, District of Columbia; F. Hoffmann-La Roche Ltd., Basel, Switzerland; Isis Pharmaceuticals, Inc., Carlsbad, California; Merck & Co., Whitehouse Station, New Jersey; the National Lipid Association, Jacksonville, Florida; Novartis International AG, Basel Switzerland; Reliant Pharmaceuticals, Inc., Liberty Corner, New Jersey; Daiichi Sankyo Co., Ltd., Tokyo, Japan; Schering-Plough Corporation, Kenilworth, New Jersey; Takeda Pharmaceutical Company Ltd., Osaka, Japan; and Wyeth, Madison, New Jersey. Dr. Stroes has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. and Novartis International AG. Dr. Steiner has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd.; Solvay, Brussels, Belgium; Ethypharm S.A., Saint-Cloud, France; and Merck Frosst Canada Ltd. (Kirkland, Quebec, Canada)/Schering-Plough Corporation. Dr. Buckley has received research grants from AstraZeneca; Merck Sharp & Dohme, Dublin, Ireland; and Pfizer, Inc., New York, New York. Dr. Buckley has received honoraria and consulting fees and/or delivered lectures for AstraZeneca; Bristol-Myers Squibb, New York, New York; F. Hoffmann-La Roche Ltd.; Novartis International AG; Pfizer, Inc.; and Sanofi-Aventis, Paris, France. Dr. Capponi has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. Dr. Burgess is an employee of Hoffmann-La Roche Inc., Nutley, New Jersey. Drs. Niesor and Kallend are employees of F. Hoffmann-La Roche Ltd. Dr. Kastelein has received research grants, honoraria, or consulting fees for professional input and/or has delivered lectures for Pfizer, Inc.; Merck Sharp & Dohme; F. Hoffmann-La Roche Ltd.; Novartis International AG; Isis Pharmaceuticals, Inc.; Kowa Pharmaceutical Company Ltd., Nagoya, Japan; Schering-Plough Corporation; and AstraZeneca.

(2009) Evan A. Stein et al.   AMERICAN JOURNAL OF CARDIOLOGY

Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

(2009) Rajesh Krishna et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

(2009) Rajesh Krishna et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib

(2009) Michael Derks et al.   CLINICAL THERAPEUTICS

In vitroandin vivoassessment of the effect of dalcetrapib on a panel of CYP substrates

(2009) Michael Derks et al.   CURRENT MEDICAL RESEARCH AND OPINION

Pharmacokinetics, Metabolism, and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Rats and Rhesus Monkeys

(2009) E. Y. Tan et al.   DRUG METABOLISM AND DISPOSITION

Metabolism and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Humans

(2009) S. Kumar et al.   DRUG METABOLISM AND DISPOSITION

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

(2008) Daniel Bloomfield et al.   AMERICAN HEART JOURNAL

Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

(2008) R Krishna et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Assessment of the CYP3A-Mediated Drug Interaction Potential of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Volunteers

(2008) Rajesh Krishna et al.   JOURNAL OF CLINICAL PHARMACOLOGY